PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...

The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

Collaboration to leverage Steritas’ STOX Suite in developing innovative treatments for autoimmune diseases.

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

Alentis’ Series D financing round this week, marks the largest ADC-related fundraising in Europe in 2024. Other notable ...

New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The U.S.

Steritas LLC, a Boston-based company committed to improving care for patients treated with steroids, has announced a multi-year licensing agreement with argenx, a global leader in immunology. The ...